In 2023, the FDA issued groundbreaking guidance on rare diseases, acknowledging the urgent need for effective treatments in the face of limited understanding and diversity within this patient population. Traditional study designs have proven inadequate for rare diseases, with challenges such as prolonged enrollment periods and ethical concerns around control arms. To address these issues, the FDA recommended novel approaches like Bayesian methods, n-of-1 clinical investigations, and master protocols. Among these, master protocols, including umbrella trials, basket trials, and platform trials, offer a unique opportunity to revolutionize rare disease research. These protocols allow for standardization, cost savings, and more efficient decision-making, ultimately leading to significant advancements in the field of rare disease treatment.
Read more from pharmaphorum.com